[go: up one dir, main page]

SG10201408485SA - Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents - Google Patents

Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Info

Publication number
SG10201408485SA
SG10201408485SA SG10201408485SA SG10201408485SA SG10201408485SA SG 10201408485S A SG10201408485S A SG 10201408485SA SG 10201408485S A SG10201408485S A SG 10201408485SA SG 10201408485S A SG10201408485S A SG 10201408485SA SG 10201408485S A SG10201408485S A SG 10201408485SA
Authority
SG
Singapore
Prior art keywords
artemisinin
chemotherapeutic agents
based drugs
anticancer combination
combinations
Prior art date
Application number
SG10201408485SA
Inventor
Claudio Pisano
Loredana Vesci
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Publication of SG10201408485SA publication Critical patent/SG10201408485SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

WO 2011/076547 PCT/EP2010/068924 The present invention relates to combinations between artemisinin-based potent anti-malarial agents, selected from the group consisting of ART, DHA and ARM, and a further chemotherapeutic drug selected from the group consisting of a camptothecin derivative, or a PARP-1 inhibitor, or an intercalating DNA agent, or an alkylating agent. Such combinations, showed medium to strong synergism in various models of cancer, in particular in NSCL.
SG10201408485SA 2009-12-23 2010-12-06 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents SG10201408485SA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09180666 2009-12-23

Publications (1)

Publication Number Publication Date
SG10201408485SA true SG10201408485SA (en) 2015-01-29

Family

ID=41647059

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201408485SA SG10201408485SA (en) 2009-12-23 2010-12-06 Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents

Country Status (21)

Country Link
US (1) US9023861B2 (en)
EP (1) EP2515898A1 (en)
JP (1) JP2013515690A (en)
KR (1) KR20120096053A (en)
CN (1) CN102665711A (en)
AR (1) AR079654A1 (en)
AU (1) AU2010335422A1 (en)
BR (1) BR112012015606A2 (en)
CA (1) CA2780591A1 (en)
EA (1) EA201200934A1 (en)
IL (1) IL220561A0 (en)
IN (1) IN2012DN03914A (en)
MX (1) MX2012006738A (en)
MY (1) MY157475A (en)
NZ (1) NZ599878A (en)
PH (1) PH12012500893A1 (en)
SG (1) SG10201408485SA (en)
TW (1) TWI482621B (en)
UA (1) UA107691C2 (en)
WO (1) WO2011076547A1 (en)
ZA (1) ZA201205360B (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9314473B2 (en) 2011-02-03 2016-04-19 Pop Test Oncology Limited Liability Company System and method for diagnosis and treatment
US9801851B2 (en) * 2012-05-23 2017-10-31 St. Jude Children's Research Hospital Methods and compositions for the treatment of BCR-ABL positive lymphoblastic leukemias
EP3137076A4 (en) * 2014-05-02 2017-12-06 Emory University Selective chemotherapy treatments and diagnostic methods related thereto
US9918972B2 (en) * 2014-12-23 2018-03-20 The University Of Maryland, Baltimore Treatment of leukemia with artemisinin derivatives and combinations with other antineoplastic agents
CN105963262B (en) * 2016-06-06 2018-11-30 北京林业大学 A kind of preparation method of amphipathic pectin-dihydroartemisinine nanoparticle
CN110051850A (en) * 2016-08-26 2019-07-26 宁国市厚普生物科技有限公司 A kind of compound is preparing the application in the drug for treating melanoma
CN109453156A (en) * 2018-11-22 2019-03-12 中国中医科学院中药研究所 A kind of anti-tumor compositions and its application, anti-tumor drug
EP3868372A1 (en) * 2020-02-19 2021-08-25 JLP Health GmbH A pharmaceutical combination of an artemisinin compound and a heme synthesis modulator for treating cancer
CN114053276B (en) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 Application of PARP inhibitor TSL-1502 intermediate TSL-1502M
CN114053271B (en) * 2020-07-30 2024-05-07 江苏天士力帝益药业有限公司 Pharmaceutical composition containing TSL-1502M and application thereof
CN114010643A (en) * 2021-11-23 2022-02-08 温州医科大学 Application of dihydroartemisinin in the preparation of antitumor drugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5578637A (en) 1995-05-03 1996-11-26 University Of Washington Methods of inhibition or killing cancer cells using an endoperoxide
SI1044977T1 (en) 1999-03-09 2002-08-31 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Camptothecin derivatives having antitumor activity
KR100390332B1 (en) 2000-08-02 2003-07-07 유원민 anti-cancer composition composed of anti-cancer and anti-malarial drugs
WO2004071506A1 (en) * 2003-02-12 2004-08-26 Georgetown University Use of artemisinin for treating tumors induced by oncogenic viruses and for treating viral infections
EP1658844A1 (en) 2004-10-19 2006-05-24 Gerold Schuler Use of artemisinin derivatives in the manufacture of a medicament for the treatment of melanoma
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US8143284B2 (en) * 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
WO2008063644A1 (en) 2006-11-20 2008-05-29 Cephalon, Inc. Method of radio-sensitizing tumors using a radio-sensitizing agent
CN101125140B (en) * 2007-09-18 2011-04-13 浙江大学 Application of dihydroartemisinin in reinforcing chemotherapy medicine antitumor curative effect
WO2009114459A2 (en) * 2008-03-10 2009-09-17 The Trustees Of The University Of Pennsylvania Anti-neoplastic combination therapeutic regimen involving co-disruption of parp pathway and mre11/rad50/nbs1 complex and compositons useful therein
CN101380325A (en) * 2008-10-23 2009-03-11 上海交通大学 Composition of artemisinin derivatives and vinorelbine and application thereof
CN101428034B (en) * 2008-12-12 2012-02-08 广州市允中投资发展有限公司 Antineoplastic combined medicament with enhancing and poison-reducing character
CN101856352A (en) * 2009-04-10 2010-10-13 中国科学院上海生命科学研究院 Synergistic effect of artemisinin and its derivatives on chemotherapeutic agents

Also Published As

Publication number Publication date
PH12012500893A1 (en) 2012-11-12
US9023861B2 (en) 2015-05-05
KR20120096053A (en) 2012-08-29
MY157475A (en) 2016-06-15
EA201200934A1 (en) 2012-12-28
BR112012015606A2 (en) 2018-05-29
UA107691C2 (en) 2015-02-10
MX2012006738A (en) 2012-07-03
ZA201205360B (en) 2013-05-29
CA2780591A1 (en) 2011-06-30
EP2515898A1 (en) 2012-10-31
IN2012DN03914A (en) 2015-09-04
AR079654A1 (en) 2012-02-08
US20120258181A1 (en) 2012-10-11
JP2013515690A (en) 2013-05-09
CN102665711A (en) 2012-09-12
IL220561A0 (en) 2012-08-30
AU2010335422A1 (en) 2012-06-07
TWI482621B (en) 2015-05-01
TW201138764A (en) 2011-11-16
WO2011076547A1 (en) 2011-06-30
NZ599878A (en) 2014-06-27

Similar Documents

Publication Publication Date Title
SG10201408485SA (en) Anticancer combination of artemisinin-based drugs and other chemotherapeutic agents
IL250445A0 (en) Nanoparticle comprising rapamycin and albumin as anticancer agent
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
IL193467A0 (en) Substituted indazole derivatives, their manufacture and use as pharmaceutical agents
HK1208227A1 (en) Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides
WO2014194195A3 (en) Cyclodextrin-based polymers for the therapeutic delivery
IL196653A (en) Camptothecin derivatives, compositions comprising them, uses thereof in the preparation of medicaments and processes for their preparation
IL213920A0 (en) 3,3'-spiroindolinone derivatives as anticancer agents
TWI372621B (en) Water-soluble iron-carbohydrate derivative complexes, the preparation thereof, and medicaments comprising them
IL195279A (en) 1-phenyl-5-[2-hydroxy-4-( hydroxy/methoxy)] phenyl-pyrazole derivatives, process for their preparation and medicaments comprising them
IL213570A (en) 8-alkoxy-s-triazolo[1,5-ɑ]pyridine derivatives and pharmaceutical compositions comprising them
IL197212A0 (en) Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent, and compositions containing the same
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
IL210975A (en) Enfumafungin derivatives, pharmaceutical compositions comprising them and use thereof for the preparation of medicaments for treating fungal infections
IL199078A (en) Substituted quinoline derivatives, pharmaceutical compositions, combinations and products comprising them, uses thereof and processes for their preparation
WO2008064060A3 (en) Dicarbonyl derivatives and methods of use
EP1994003A4 (en) Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them .
WO2010082789A3 (en) Anticancer compositions comprising cedrol in nanoparticle form
WO2008045294A3 (en) Boosting immunity
HK1126218A (en) Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them.
DE602007009396D1 (en) Camptothecinderivate mit antitumorwirkung